Influx Health.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

Which are the latest news on Influx Health.?

Why is Influx Healthtech Ltd falling/rising?

As of 25-May, Influx Healthtech Ltd's stock price is at 239.40, down 4.16%, and has significantly underperformed compared to the Sensex, which has risen by 1.61%. Despite a positive year-to-date performance, recent trends show investor concerns as the stock is below its short-term moving averages and has not benefited from increased investor participation.

As of 25-May, Influx Healthtech Ltd's stock price is falling, currently at 239.40, reflecting a change of -10.4 or -4.16%. The stock has underperformed significantly compared to the benchmark Sensex, which has increased by 1.61% over the past week, while Influx Healthtech Ltd has dropped by 14.65%. Over the past month, the stock has also declined by 5.97%, contrasting with the Sensex's modest gain of 0.56%. <BR><BR>Despite a positive year-to-date performance of +5.88%, the recent downward trend indicates investor concerns, particularly as the stock is currently lower than its 5-day, 20-day, and 50-day moving averages, although it remains above the 100-day and 200-day moving averages. Additionally, while there has been a notable increase in investor participation, with delivery volume rising by 100.85% against the 5-day average, this has not translated into a positive price movement. The stock's performance today has also been marked by a significant underperformance against its sector, further contributing to the decline in its price.